Regeneron faces class action after Phase 3 melanoma trial failure wipes out $11 billion

The suit targets statements made between Aug. 1, 2025 and May 15, 2026 over Fianlimab and Libtayo, and sets a Sept. 14, 2026 lead plaintiff deadline.

24d ago